CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedAC
American Cancer Society BrightEdge
Activity from announced rounds
Activity in this selectionbrighteye-258745be
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $224.5M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionTippingPoint Biosciences
Develops novel drug discovery platform to target epigenetic targets in pediatric brain cancer
$4.5MSeed
Role not disclosed